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group outcomes in randomised trials in paediatric
oncology provides evidence that historically
controlled studies are biased in favour of the
novel treatment
Veronica Moroz1, Jayne S Wilson1, Pamela Kearns1 and Keith Wheatley1,2*Abstract
Background: Historically controlled studies are commonly undertaken in paediatric oncology, despite their
potential biases. Our aim was to compare the outcome of the control group in randomised controlled trials (RCTs)
in paediatric oncology with those anticipated in the sample size calculations in the protocols. Our rationale was
that, had these RCTs been performed as historical control studies instead, the available outcome data used to
calculate the sample size in the RCT would have been used as the historical control outcome data.
Methods: A systematic search was undertaken for published paediatric oncology RCTs using the Cochrane Central
Register of Controlled Trials (CENTRAL) database from its inception up to July 2013. Data on sample size
assumptions and observed outcomes (timetoevent and proportions) were extracted to calculate differences
between randomised and historical control outcomes, and a one-sample t-test was employed to assess whether
the difference between anticipated and observed control groups differed from zero.
Results: Forty-eight randomised questions were included. The median year of publication was 2005, and the range
was from 1976 to 2010. There were 31 superiority and 11 equivalence/noninferiority randomised questions with
time-to-event outcomes. The median absolute difference between observed and anticipated control outcomes was
5.0% (range: −23 to +34), and the mean difference was 3.8% (95% CI: +0.57 to +7.0; P = 0.022).
Conclusions: Because the observed control group (that is, standard treatment arm) in RCTs performed better than
anticipated, we found that historically controlled studies that used similar assumptions for the standard treatment
were likely to overestimate the benefit of new treatments, potentially leading to children with cancer being given
ineffective therapy that may have additional toxicity.
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Randomised controlled trials (RCTs) are considered the
gold standard for the evaluation of medical treatments,
as the process of randomisation provides an unbiased
comparator group with which to compare the novel
treatment [1]. Despite this, historically controlled studies
(HCSs) are commonly undertaken in paediatric oncology
(PO). This is due to a widespread belief that RCTs can-
not be performed in rare diseases, because there will be
too few patients [2]. This belief persists despite the well-
known potential biases in HCSs; that is, other factors
change over time, which introduces confounding.
Trial sample size is the planned number of patients to
be included in a study, and its determination is import-
ant in clinical trial design. Elements of the sample size
calculation include anticipated outcomes for the primary
outcome measure in the control and experimental
groups, along with the likelihood of detecting or missing
an effect of this size (type I error (α) and type II error
(β)). These assumptions should be reported—though
sometimes they are not—in the main trial publication.
Our aim was to compare the outcomes of the control
groups in RCTs in PO with those anticipated in the sam-
ple size calculations in the trial protocols. The rationale
was that, had these RCTs been performed as HCSs in-
stead, the available outcome data that were used to cal-
culate the sample size in the RCTs would have been
used as the HCS outcome data.
Methods
Search strategy
The sample of trials was derived from a systematic search
for published PO RCTs using the Cochrane Central
Register of Controlled Trials (CENTRAL) database from
the database’s inception up to July 2013. The search terms
were ‘randomi?ed’ plus the disease name in all fields. For
diseases which affect both children and adults, the search
was restricted to the paediatric population. Articles in a
foreign language were excluded. The search results were
assessed for eligibility by a single reviewer on the basis of
the title and abstract, and they were checked by a second
reviewer.
Inclusion criteria
Superiority, equivalence and noninferiority RCTs that re-
ported either time-to-event or dichotomous outcomes
were included. Dichotomous outcomes were restricted
to ‘tumour response’, as this is a common primary out-
come in clinical trials in cancer. Both completed trials
(that is, those that achieved target sample size) and trials
that had been stopped early were included. In publica-
tions in which the authors reported more than one ran-
domised question (RQ), each question was considered
separately. In the case of 2×2 factorial and three-armdesigns, each randomisation arm was included as a sep-
arate RQ because two separate clinical decisions would
be made in these trial designs. For diseases that affect
both adults and children, only trials including predomin-
antly children were considered, though trials with a
small proportion of adults were included. To calculate
both the absolute and relative differences between the
randomised and historical control (HC) comparisons,
data on sample size assumptions and observed outcomes
were required; any RQ not including these was excluded.
Data extraction
A data extraction sheet was designed to record the follow-
ing data: (1) disease search term, (2) year of publication,
(3) trial type (superiority, equivalence or noninferiority),
(4) control and experimental treatments, (5) whether the
trial included any adults, (6) primary outcome (as per the
endpoint used in sample size calculations) and type of pri-
mary outcome (dichotomous or time to event), (7) antici-
pated control rate of events, (8) anticipated treatment
effect, (9) types I and II errors, (10) target and recruited
number of patients (as per the primary outcome analysis),
(11) observed control and experimental arm event rates,
(12) observed hazard ratio, (13) absolute difference be-
tween arms and (14) P-value (and whether the results
were statistically significant for the primary outcome).
Where the authors presented more than one sample size
calculation (for example, the trial had been redesigned for
a different outcome based on a data monitoring commit-
tee recommendation), the original assumptions were
taken. Where authors presented the observed event rate
that was measured at time points different from those spe-
cified in the sample size calculation, we estimated the rates
for the prespecified time point based on Kaplan-Meier
survival plots. If there were any design ambiguities in the
published articles, the original protocols were consulted
where possible. Data extraction was checked by an inde-
pendent second reviewer; discrepancies were resolved by
discussion or taken to a third, blinded reviewer.
Analysis
Absolute differences
Absolute control arm differences were calculated using
the anticipated control rate from the sample size calcula-
tion and the observed control rate from the results sec-
tion of the trial report (observed − anticipated control)
to measure the accuracy of the assumptions. We investi-
gated the absolute differences for the randomised and
HC comparison by looking at the differences between
the experimental treatment arm and both the observed
control rate and the anticipated control rate reported in
the sample size calculation. Sensitivity analyses were per-
formed by excluding RQs that formed a three-arm trial
and/or trials with a factorial design. A one-sample t-test
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ipated and observed control groups differed from zero.
Spearman’s correlation coefficients were used to quantify
the correlations between variables. Disease prognosis for
survival outcomes was calculated as estimated observed
treatment and control outcomes for 3 years, assuming
an exponential distribution.
Relative differences
For dichotomous outcomes, risk ratios (RRs) were calcu-
lated. For both randomised and HC comparison, we esti-
mated RRs by dividing the event rate of a control group
(observed or anticipated) by the event rate in the experi-
mental arm (RR < 1 represents a benefit for the experi-
mental arm). For time-to-event outcomes, hazard ratios
(HRs) were used to assess relative differences between
treatment and control groups. The presented HRs for the
primary analysis were used if reported. If only the number
of events in each arm (or in total) were presented in the
RQ publications with corresponding P-values for the Cox
model and the Mantel-Haenszel and logrank tests, we
used methods described by Tierney and colleagues [3] to
estimate HRs for the randomised comparison. In cases
where data were available only for proportions of survival
at a particular time point, we estimated the HR using the
formula ln(treatment survival)/ln(observed control sur-
vival). For the HC comparison, we estimated HRs by
calculating ln(treatment survival)/ln(anticipated control
survival). The analysis was undertaken using Stata version
11 software (StataCorp, College Station, TX, USA).Figure 1 Flowchart of the trial selection process. RCT, Randomised con
and [] represent RQs.Results
Searches
Fifteen disease areas were searched electronically, which
returned 1,083 abstracts. Forty publications with forty-
eight RQs were included in the analysis (Figure 1). Lymph-
oma yielded the most RQs, accounting for 28% of all the
RQs (Table 1).
Characteristics of randomised questions
Table 2 describes the characteristics of the included
RQs. The median year of publication was 2005, and the
range was from 1976 to 2010 (Additional file 1). There
were 31 superiority and 11 equivalence/noninferiority
RQs with time-to-event outcomes. Time-to-event out-
comes included event-free (a combination of progres-
sion, relapse, second malignancy, remission failure and/
or death due to any cause), disease-free, relapse-free,
metastasis-free, failure-free, progression-free and overall
survival. The endpoint definitions used were those
employed in each trial. There were six superiority trials
with dichotomous primary endpoints, which included
histologic, overall, rapid, complete and partial response
variables. The median α and power were standard at 5%
and 80%, respectively. There were six trials that had
power of less than 80% and four with α above 5%. The
median delta (Δ) and noninferiority margins were 15%
(range: 6% to 25%) and 10% (range: 7% to 17%), respect-
ively. The mean total design sample size was 240 (range:
92 to 1,800), and the recruited sample size was 221
(range: 36 to 2,618). Ten RQs included patients oldertrolled trial; RQ, Randomised question. Note: () represent publications
Table 1 Included randomised questions by searched term
Search term Randomised questions
n (%)
Acute lymphoblastic leukaemia 6 13
Acute myeloid leukaemia 2 4
Ependymoma 0 0
Ewing’s sarcoma 2 4
Germ cell 0 0
Glioma 0 0
Hepatoblastoma 0 0
Langerhans cell histiocytosis 1 2
Lymphoma 13 27
Medulloblastoma 4 8
Neuroblastoma 4 8
Osteosarcoma 6 13
Retinoblastoma 0 0
Rhabdomyosarcoma 7 15
Wilms’ tumour 3 6
Total 48 100
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als [4-6], and two were parts of a three-arm trial [7].
Ten RQs gave ‘extra’ sample size calculations. Six of
these gave calculations for a secondary outcome and/or
calculations for the actual recruited number of patients
[5,8-12]; two gave power for the same sample size for a
different Δ [13,14]; and one trial was redesigned for aTable 2 Characteristics of the included randomised
questions
Characteristics of included RQs (N = 48) Values
Year of publication (based on 40 publications),
median (range)
2005 (1976 to 2010)
Trial type and primary outcome type
Superiority, timetoevent 31
Equivalence/noninferiority, timetoevent 11
Superiority, dichotomous 6
Power
Median (range) 80% (73% to 99%)
Number of trials <80% 6
α
Median (range) 5% (5% to 20%)
Number of trials >5% 3
Δ (superiority), median (range) 15% (6% to 25%)
Noninferiority margin, median (range) 10% (7% to 17%)
Total design sample size, median (range) 240 (92 to 1,800)
Total recruited sample, median (range) 221 (36 to 2,618)different primary outcome based on data monitoring
committee recommendations [15]. One trial gave sample
size calculations for two outcomes (overall and event-
free survival (EFS)), and a blinded reviewer selected EFS
for use in the analysis [16]. Two trials were stopped
early, and one employed a 2:1 allocation ratio. Owing to
the availability of protocols within the trials unit, the
protocols for three RQs [4,17] were checked for the time
point of the anticipated control rate. The observed con-
trol rates for the prespecified time point were estimated
using available Kaplan-Meier plots for 17 RQs.
For 2 of 48 RQs, the P-values for the primary compari-
son were not presented. Nine superiority and four nonin-
feriority/equivalence RQs yielded a P-value <0.05 (eight
superiority RQs favoured controls, two showed equiva-
lence and one concluded noninferiority).
Absolute difference for control group
The results described in this section are based on 47
RQs, as two of the randomised comparisons came from
a three-arm trial; hence, only one control was used to
compare two separate treatments.
Figure 2 shows the distribution of absolute differences
between the observed and anticipated control group,
where a positive change means that the observed control
arm did better than anticipated. In 34 trials, the ob-
served control group did better than anticipated (in 12
cases, there was ≥10% absolute difference). The observed
control group did worse (by ≥10% in 6) in 12 trials, and
the outcome was the same as anticipated in 1 trial. The
median absolute difference between the observed control
and anticipated control outcomes for all 47 trials was
5.0% (range: −23 to +34), and the mean difference was
3.8% (95% confidence interval (CI): +0.57 to +7.0); this
finding was statistically significant (P = 0.022). A sensitiv-
ity analysis excluding five RQs that were parts of factor-
ial trials did not change the results. For time-to-event
outcomes, the median and mean differences were 5.0%
(range: −23 to +34) and 4.4% (95% CI: +0.40 to +8.4), re-
spectively, in the superiority trials; it was 3.0% (range: −15
to +13) and 1.8% (95% CI: −2.9 to +6.5), respectively, in
equivalence and noninferiority trials. For trials with a
dichotomous endpoint, the median and mean differences
were 7.7% (range: −21 to +31) and 4.6% (95% CI: −15
to +24), respectively.
The absolute differences between the observed and the
anticipated controls and trial size (number of recruited
patients) were not related, with a Spearman’s correlation
coefficient of 0.04 (Additional file 2). Similar results were
found for the year of trial publication, with a correlation
coefficient −0.07 (Additional file 2). There was a positive
association between the control group differences and
the prognosis of the disease (calculated as the average of
observed treatment and control outcomes), with a
Median = 5%
Mean = 3.8%
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Figure 2 Distribution of absolute differences between observed and anticipated control (%). RQ, Randomised question.
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is, the trials with better prognosis had larger positive
differences.
Absolute differences for control versus experimental
groups
Figure 4 graphically shows the absolute differences for the
randomised and HC comparisons. The overall median ab-
solute difference (based on 48 RQs) between the experi-
mental treatment and observed control groups was 2.0
(range: −16 to +49) in the randomised comparison and for
the difference between the experimental treatment and the
anticipated control group outcome was 6.5% (range: −20
to +34). The means were 3.2% (95% CI: +0.18 to +6.3) andC o rre la t io n C oe f f ic ie nt  =  0.3 4
p  =  0 .02 0
-2 0
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Figure 3 Scatter plot for control difference and disease prognosis (107.0% (95% CI: +3.9 to +10.1), respectively. A sensitivity
analysis excluding seven RQs that were parts of factorial
and three-arm designs did not change the results. For
superiority trials with time-to-event outcomes, the me-
dian differences for randomised comparison were 2.4%
(range: −12 to +49) and 7.9% (range: −20 to +29) for
HC and the means were 4.1% (95% CI: +0.001 to +8.1)
and 8.4% (95% CI: +4.68 to +12.1), respectively. The
median difference for the equivalence or noninferiority
trials was −1.0% (range: −16 to +6.0) for randomised
comparison and 0.9% (range: −13 to +11) for HC; the
means were −1.8% (95% CI: −6.0 to +2.4) and 0.04%
(95% CI: −4.5 to +4.6), respectively. For the trials with
dichotomous outcomes, the medians were 11% (range: −126 0 80 1 00
s is  (% )
 R es u lts  C o nt r o l) /2
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Figure 4 Absolute differences for randomised question (RQ; left) and historical control (right) comparison.
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http://www.trialsjournal.com/content/15/1/481to +21) and 13% (range: −8.0 to +34) for randomised
and HC, respectively; the means were 8.2% (95% CI: −4.3
to +21) and 13% (95% CI: −1.9 to +27), respectively.Relative differences
Figure 5 shows HRs for time-to-event outcomes and RRs
for the dichotomous outcomes for the randomised and
HC comparisons. The overall median ratios for the rando-
mised comparisons were 0.91 (range: 0.16 to 3.6) and 0.78
(range: 0.11 to 2.3) for HC; the mean values were 0.97
(95% CI: 0.83 to 1.12) and 0.85 (95% CI: 0.73 to 0.96),
respectively. When we restricted this to superiority trials
(n = 31) with time-to-event outcomes, the median HR for
randomised was 0.91 (range: 0.16 to 1.7), and it was 0.77
(range: 0.11 to 2.3) for HC comparison. The means were
0.89 (95% CI: 0.77 to 1.01) and 0.78 (95% CI: 0.64 to 0.92),
respectively. For equivalence/noninferiority trials with
time-to-event outcomes, the median HRs were 0.94 and
0.91 for randomised and HC comparison, respectively
(means: 1.26 and 1.06); for dichotomous outcomes, the
RRs were 0.80 and 0.81, respectively (means: 0.86 and
0.81).Discussion
Summary of findings
The potential biases in HC studies are well known and in-
clude confounding with other factors that change over
time [18-20]. In this research, we attempted to quantify
the effect of these biases in the field of PO. We provide
evidence that the use of data from a historical population
for comparison with a group of patients who received a
novel treatment is likely to lead to experimental treat-
ments’ appearing more effective than they actually are.
Of the 48 randomised comparisons analysed, we found
that 73% of the control arms performed better than had
been anticipated in the sample size calculation and that,
on average, the control group did 3.8% better than antic-
ipated. Furthermore, whereas the median difference was
5%, there was wide variation, with the control arm occa-
sionally performing more than 10% better, or worse,
than anticipated, meaning that, in each individual case,
it would not be possible to simply adjust the anticipated
control group outcome by +3.8% in HCSs. If the ob-
served control group outcome was actually the same as
that anticipated, we would expect to see random vari-
ation (due to sampling error) around this estimate (the
mean difference would be zero). The fact that, based on
an analysis of 48 randomised comparisons, the control
group did 3.8% better on average indicates that what we
are seeing is not explained by chance variation, but ra-
ther represents a systematic underestimation, on aver-
age, in the sample size calculation of the control group’s
outcome.The absolute difference between the new intervention
and observed control showed that the median for the
new intervention was 2.0% better than the control,
whereas, when HC data were used, this difference in-
creased to 6.5%. In relative terms, when the randomised
comparison was used, the median ratio was 0.91 in
favour of the treatment arm and 0.78 when the HC was
used, implying that a larger treatment effect would be
obtained with HCSs, potentially leading to erroneous
conclusions regarding treatment efficacy.
The association between the control differences (antic-
ipated and observed rates) and factors such as total
number of patients in the trial, year of publication and
disease prognosis was explored to investigate if larger
differences were associated with smaller or larger trials,
earlier or later trials or better or worse disease progno-
sis. There was a positive association between control dif-
ferences and prognosis of the disease, though why this
should be the case is unclear.
In HCSs, outcome data from independently conducted
interventional studies are compared to derive a compari-
son of treatment efficacy [18,20]. The new treatment arm,
usually prospectively collected, is compared to a control
group of previous patients [21] (obtained from either pub-
lished or unpublished sources [22]), with the underlying
assumption that the treatment effect in the HC group
would represent a valid comparison for the experimental
treatment. HCSs require fewer patients and are quicker
and, hence, cheaper to perform than RCTs [23]. These
qualities are attractive in childhood cancer research. Most
childhood cancers are rare conditions, which causes diffi-
culty because of the limited number of patients available
to participate in trials, creating ethical [23,24], statistical
and funding [25,26] challenges. However, critics of HCSs
suggest that this is a much less desirable method of mak-
ing comparisons and is prone to many forms of unpredict-
able bias, as various factors may change over time, such as
supportive care, demographic characteristics and diagnos-
tic criteria [18,27]. This ‘temporal drift effect’ [28] results
in a population-wide shift of prognostic factors question-
ing comparability of HC and randomised control and
hence the validity of the results from HCSs.
Pinpointing the exact cause of the differences between
effect estimates of observed control and anticipated con-
trol is difficult, particularly in PO, where management is
often multifactorial and several factors may change over
time. Changes in surgical technique (or selection of dif-
ferent types of patient for surgery); radiotherapy (or se-
lection of different types of patient for radiotherapy);
supportive care, such as improved antibiotic or blood
product support; diagnosis (even if earlier diagnosis does
not lead to better prognosis, it will result in patients
appearing to live longer(time lag bias); staging (the wide-
spread introduction of novel imaging methods means
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sponse to treatment may change (stage migration)) may
confound the historical comparison and introduce bias.
Previous work
Differences between HCSs and RCTs have been studied
previously, and the results reported reflect our present
findings. In 1996, Bhansali et al. [29] meta-analysed
HCSs and RCTs in which cisplatin-based therapies in
oesophageal cancer had been assessed and found a ‘gross
overestimation of treatment effect’ for cisplatin, with the
historically controlled meta-analysis giving a statistically
significant odds ratio (OR) of 0.32 (95% CI: 0.24 to 0.42)
compared to the RCT meta-analysis OR of 0.96 (95% CI:
0.75 to 1.22). In 1986, Diehl and Perry [23] matched
RCTs with HCSs covering six cancer types and com-
pared survival rates, calculating whether there was a
10% difference in survival between the matched pairs. It
was found that there was a greater than 10% difference
in 38% of the pairs, and the authors concluded, ‘the
assumption that historical control groups may replace
randomized concurrent control groups is not valid’
(p 1114). Our results show that HCSs can overestimate
treatment benefit compared to randomised comparisons
by as much as 34% in absolute terms and 13% in relative
terms. These larger treatment effects could be the result
of selection bias, as control groups in an RCT need to
meet eligibility criteria, which are generally more strin-
gent [20]. This also indicates that the results of the
HCSs are not a reflection of advantageous experimental
treatment, but to a certain extent are due to a flawed
design.
Some of the authors of the trials included in our data
set also acknowledged the observed differences between
anticipated and observed rates (for example, Souhami
et al. [30], Evans et al. [31]). A good example of this is
the oldest study included in our analysis, published in
1976, which underestimated the control 2-year relapse-
free survival by 34%, assuming 50% and observing 84%
[31]. The authors concluded, ‘[The result] points up the
value of including in the study an untreated [standard
treatment] control arm. An overall better survival ex-
perience obtained in the trial would have been attributed
erroneously to CPM therapy [new treatment] had histor-
ical controls been used’ (p 659).
Our result differs from that of a previous study in
which the researchers looked into the reporting of sam-
ple size calculation in RCTs. Charles and colleagues [32]
found a median relative difference (calculated as [antici-
pated − observed]/anticipated) of 2.0% (interquartile
range (IQR): −15% to 21%) in studies of common adult
cancers, whereas we found this difference to be −7.5%
(IQR: −15% to 1.5%). The HC data used in our work are
probably older than the HC data used in Charles et al.’sset of trials; thus, the effect of the ‘temporal shift’ may
be greater. This could reflect the differences in the trial
types studied by Charles et al. and ourselves; that is, re-
cruitment for the ones we researched, dealing with rare
diseases in PO, take longer to recruit.
Strengths and limitations
We used a reproducible methodology following a proto-
col, with the studies identified and the data extracted in
a systematic fashion and checked by two people.
Our analyses are based on 48 RQs. However, the data
represented only 50% of the published paediatric RCTs
that we identified in our search. We found 92 publications
describing 107 RQs with time-to-event and dichotomous
outcomes. Of these, 76 RQs reported formal sample size
calculations, but only 48 gave detailed parameters. This
underreporting is higher than that observed by Charles
and colleagues [32], who undertook a survey of how many
RCTs reported sample size calculations and found that
19% of trials did not report control group assumptions ad-
equately. One reason for this may be that Charles et al.
conducted their survey between 2005 and 2006, whereas
our studies went as far back as 1976. Indeed, the median
year of publication of our included articles was 2005
versus 1995 for excluded RQs due to missing sample size
information, suggesting that reporting of sample size cal-
culations has improved in recent years.
Owing to the lack of information on the uncertainty of
the HC estimate (that is, CIs around the HC estimate),
in many cases, we were unable to assess whether the re-
sult of the HC scenario was consistent with that of the
randomised comparison; that is, the total number of pa-
tients on which the anticipated control rate was based
was not typically given. A final limitation is that for sev-
eral RQs, we estimated HRs for the randomised and HC
comparison using just one time point and acknowledge
that these HRs would not be the same as those based on
time-to-event analysis; however, this did not introduce
bias, as the error could go in either direction.
Recommendations
We and others have shown that the underlying assump-
tion that the treatment effect in an HC group is equiva-
lent (taking into account sampling variation) to that of a
randomised concurrent control group is erroneous. Des-
pite this, support of this study design remains popular,
particularly in PO [2], with a reluctance undertake RCTs
instead. This reluctance appears to stem from a rigid be-
lief in some quarters that an RCT can be done only if
there are sufficient patients for a trial to be designed
using conventional parameters of 80% power and 5% α.
An alternative view, to which we subscribe, is that any
randomised evidence is better than none; that is, a small
randomised trial will provide an unbiased estimate of
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http://www.trialsjournal.com/content/15/1/481the treatment effect (assuming that it is well conducted
and analysed), even if it does have wider confidence in-
tervals due to the smaller number of patients and events
analysed. As we have demonstrated, the potential of
HCs to introduce biases due to the confounding factors
discussed above give unpredictable and often large dif-
ferences in effect estimates compared to randomised
concurrent controls. Hence, RCTs with alternative as-
sumptions (for example, a relaxed α) or novel designs
(for example, Bayesian) that give unbiased estimates of
treatment effect should be considered whenever pos-
sible, although it needs to be accepted that, with small
numbers and wide confidence intervals, cautious inter-
pretation may be needed and definitive conclusions may
not be possible. They would not be possible with HCSs
either, but for additional reasons (such as biases)).
Conclusions
Because the observed control group (that is, standard
treatment arm) in RCTs did better than anticipated, we
conclude that HCSs that use similar assumptions for the
standard treatment are likely to overestimate the benefit
of new treatments, potentially leading to children with
cancer being given ineffective therapy that may have
additional toxicity.
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